Medicare Covers Obesity Now. Almost Nobody Knows.

You need Part D, either a stand-alone drug plan or a Medicare Advantage plan with drug coverage. The Bridge works with any Part D plan; plans do not opt in and do not carry the cost. Medicare Advantage plans may also offer supplemental nutrition or fitness benefits on top of everything below.

Pitfall: a patient with Part A and B only, no drug plan, cannot use the Bridge.

Four diagnoses route a GLP-1 through regular Part D instead of the Bridge: type 2 diabetes (Ozempic, Mounjaro, and others), established cardiovascular disease with BMI 27 or higher (Wegovy), moderate-to-severe obstructive sleep apnea with obesity (Zepbound), and noncirrhotic MASH with fibrosis (Wegovy).

On this route the plan's own cost sharing applies, which can be higher than $50, but the 2026 out-of-pocket cap of $2,100 applies. Patients with type 2 diabetes, moderate-to-severe sleep apnea, or MASH are excluded from the Bridge by rule because this route exists.

BMI 35 or higher: eligible with no additional condition.

BMI 30 to 34.9: eligible with one of heart failure with preserved ejection fraction, uncontrolled hypertension (above 140 systolic or 90 diastolic despite two or more medications), or chronic kidney disease stage 3a or worse.

BMI 27 to 29.9: eligible with one of prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease.

BMI is measured at the start of therapy. Age 18 or older. Pitfall: a patient with BMI 32 and none of the tier 2 conditions does not qualify, even though the FDA label would allow treatment at BMI 27 with any weight-related condition.

The Bridge requires the drug to be prescribed alongside current and ongoing lifestyle modification with structured nutrition and physical activity, consistent with the FDA label. The prescriber attests to it.

Medicare already pays for the pieces: Intensive Behavioral Therapy in primary care (up to 22 visits, no copay), the Medicare Diabetes Prevention Program for anyone in tier 3 with prediabetes, and medical nutrition therapy with a dietitian for anyone in tier 2 with CKD. Enrolling in one of these before or at the first prescription makes the attestation true and the chart clean.

The prescription is written for Wegovy (injection or tablets), Zepbound in the KwikPen, or Foundayo, for the weight-management indication. The pharmacy submits the claim first. That triggers a prior authorization request to the prescriber, typically within 72 hours, and the decision goes to both patient and prescriber within 72 hours.

Pitfall: there is no appeal. A denial can only be resubmitted with corrected information. Zepbound vials and single-dose pens are not covered under the Bridge.

$50 per prescription. It is a flat copay, not a percentage. It does not count toward the Part D deductible or the $2,100 out-of-pocket cap, because the Bridge sits outside Part D.

If a patient does not qualify, the manufacturers' direct-pay programs remain the fallback, and the price of those has changed several times since the November 2025 pricing agreements. Check the current figure rather than quoting an old one.

Medicare has covered bariatric surgery since 2006 under National Coverage Determination 100.1: BMI 35 or higher, at least one obesity-related comorbidity, and documented prior unsuccessful medical treatment. Roux-en-Y gastric bypass, sleeve gastrectomy, biliopancreatic diversion with duodenal switch, and adjustable gastric banding are covered.

Surgery and medication are not either-or. Patients with weight regain after surgery are increasingly treated with GLP-1s, and the Bridge does not exclude prior surgery.

The Bridge ends December 31, 2027. The BALANCE Model's Part D component, which was meant to take over in 2027, was delayed indefinitely in April 2026. As of September 2026 there is no announced Medicare drug coverage for obesity itself after the Bridge ends.

Plan for it at the first visit: what happens to the prescription in 2028, whether a comorbidity route will exist by then, and what the maintenance plan looks like if medication access lapses. Coverage should follow medical need, and the only way that becomes permanent is a change in the statute.

AHCCCS covers GLP-1s for type 2 diabetes and covers Wegovy with prior authorization for cardiovascular risk reduction. It does not cover them for obesity itself. In December 2025 an AHCCCS representative reported the agency spends about $73 million a year on GLP-1s, $13 million of it from the state general fund, with federal price reductions projected to lower that to about $23 million overall.

The Obesity Treatment Study Committee created by SB 1711 (2025) finished its work: it adopted recommendations on December 17, 2025, including recognizing obesity as a chronic disease and creating a permanent advisory council. SB 1621 (2026), which would have created that council, passed the Senate on March 11, 2026 and died in the House. Arizona does not currently have an active study committee. It is not waiting on evidence. It is waiting on a vote.

Announced December 23, 2025 by the CMS Innovation Center. For Medicaid, a voluntary model in which CMS negotiates a confidential net price with manufacturers, states adopt standardized coverage criteria matching the Medicare Bridge grid, and enrollees receive a manufacturer-funded lifestyle program at no cost. States could begin May 1, 2026, can join through January 1, 2027, and the model runs through December 31, 2031.

As of the CMS model page update on August 14, 2026, no participating state had been publicly named. The Part D half of the model was delayed indefinitely on April 21, 2026. Do not use "BALANCE" as the name for the $50 Medicare program; they are different things.